Patients who’d seen substantial hair regrowth in the first part of Nektar’s trial had a “deepening” treatment response, extending a comeback bid that’s caused shares to skyrocket over the last year.

​Read More

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of the drug, known as MK-2010, while four of nine patients …​ ​Read More

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Did you know it’s National Library Week? Of course you did, you look so studious. To honor the thrill of reading and learning, STAT is offering 60% off our subscription for your first year. Check it out, visit a library, and as always, say hello: bob.herman@statnews.com.

A contentious fight over drug price transparency

Anna Yeo/STAT

The phalanx of lobbyists representing pharmacy benefit managers and health insurers has mounted stiff opposition to a federal proposal that attempts to pry open the black box of prescription drug prices.

Continue to STAT+ to read the full story…

​Read More